Planned closure for Emergencies from 12pm onwards New entrance to the practice PLANNED CLOSURE FOR TRAINING: Wednesday 24th January from 12pm-6.30pm Update on our Pilot on Access 22/1/2024 Reduction in waiting times and improving access Merry Christmas and a Happy New Year Children in Need 2023 THE NHS APP AND ACCESS TO YOUR ONLINE RECORDS IMPORTANT UPDATE FOR OUR PATIENTS REGARDING COVID SECURE MEASURES 10/10/2023 Accurx online triage system
The NHS is offering new antibody and antiviral treatments to people with coronavirus (COVID-19) who are at highest risk of becoming seriously ill.
2 types of COVID-19 treatment are available:
These treatments can help some people manage their COVID-19 symptoms and reduce the risk of becoming seriously ill.
Molnupiravir is an antiviral ORAL medicine.
Sotrovimab is a biological medicine. It is also known as a neutralising monoclonal antibody (nMAb). It is only available to patients who are at the highest risk from Covid-19 or SHIELDED.
A list of those considered to be at the highest risk is given below.
Where an nMAB is contraindicated, not recommended or the administration of a nMAB is not possible, patients may be treated with a five-day course of molnupiravir, provided the onset of symptoms is in the last 5 days.
It is given intravenously, within 5 days of symptom onset.
One trial found a single dose of sotrovimab reduced the risk of hospitalisation and death by 85% when given to high risk unvaccinated hospitalised patients with Covid 19.